Novartis AG - Company Profile

Powered by

All the data and insights you need on Novartis AG in one report.

  • Save hours of research time and resources with
    our up-to-date Novartis AG Strategy Report

  • Understand Novartis AG position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Gain a 360-degree view of Novartis AG and make more informed decisions for your business Gain a 360-degree view of Novartis AG and make more informed decisions for your business Find out more
Headquarters Switzerland

Address Lichtstrasse 35, Basel, 4056


Telephone 41 61 3241111

No of Employees 76,057

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange NOVN (SWF)

Revenue (2023) $46.7B 7.6% (2023 vs 2022)

EPS XYZ

Net Income (2023) XYZ 113.5% (2023 vs 2022)

Market Cap* $222.2B

Net Profit Margin (2023) XYZ 98.6% (2023 vs 2022)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Novartis AG premium industry data and analytics

6,800+

Clinical Trials

Determine Novartis AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2,600+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Novartis AG’s relevant decision makers and contact details.

2,200+

Catalyst Calendar

Proactively evaluate Novartis AG’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

1,400+

Marketed Drugs

Understand Novartis AG’s commercialized product portfolio to stay one step ahead of the market.

910+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

730+

Pipeline Drugs

Identify which of Novartis AG’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

180+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

120+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Novartis AG and assess market opportunity for new entrants with patient population 8-year forecasts.

14+

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Novartis AG (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Novartis AG’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Generic Medicines and Biosimilars Cibacen (benazepril hydrochloride)
Pharmaceuticals: Exforge (valsartan and amlodipine besylate)
Cancer Exforge HCT (valsartan, amlodipine besylate and hydrochlorothiazide)
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Novartis AG portfolio and identify potential areas for collaboration Understand Novartis AG portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Corporate Changes/Expansions In March, the company invested US$256 million to expand a biopharmaceutical manufacturing facility in Singapore.
2024 Contracts/Agreements In February, the company entered into an agreement to acquire MorphoSys AG for US$2.9 billion.
2024 Contracts/Agreements In February, the company and Erasca entered into two clinical trial collaborations and supply agreements for the MEK inhibitor trametinib.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Novartis AG Johnson & Johnson F. Hoffmann-La Roche Ltd Merck & Co Inc Pfizer Inc
Headquarters Switzerland United States of America Switzerland United States of America United States of America
City Basel New Brunswick Basel Kenilworth New York
State/Province - New Jersey - New Jersey New York
No. of Employees 76,057 131,900 103,605 72,000 88,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Joerg Reinhardt, Ph.D. Chairman Executive Board 2013 67
Vasant Narasimhan, M.D. Chief Executive Officer Senior Management 2018 47
Harry Kirsch Chief Financial Officer Senior Management 2013 58
Karen L. Hale Chief Legal Officer Senior Management 2021 55
Shreeram Aradhye Chief Medical Officer; President - Global Drug Development Senior Management 2022 61
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Novartis AG key executives to enhance your sales strategy Gain insight into Novartis AG key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward